impact of the embark trial on the management of non-metastatic prostate cancer
Published 4 days ago • 71 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
1:46
evaluating the impact of treatment on sexual activity in prostate cancer
-
2:31
embark: treatment suspension and health-related quality of life in prostate cancer
-
3:54
probio: a biomarker driven study in patients with metastatic prostate cancer
-
3:06
phase ii trial of nivolumab with soc in the management of gg5 prostate cancer
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
6:40
understanding your cancer prognosis
-
27:49
how fitness impacts prostate cancer – 2023 zero prostate cancer summit
-
26:44
prostate cancer prognosis and survival
-
16:58
prostate cancer 2021 (part 1): comprehensive review
-
1:32
metastatic prostate cancer treatment: a paradigm shift
-
1:56
predicting os with pfs in pancreatic cancer in the napoleon-1 and -2 trials
-
4:49
advances in prevention and treatment of bone metastases in prostate cancer
-
4:51
advanced & metastatic prostate cancer at asco gu
-
8:56
abiraterone in metastatic prostate cancer
-
2:20
survivorship in metastatic prostate cancer
-
5:16
enzamet: enzalutamide for metastatic prostate cancer
-
2:46
first-line treatments in metastatic prostate cancer
-
3:57
update on arches trial: implications for prostate cancer treatment
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
0:53
embark: subset analysis of enzalutamide versus leuprolide in prostate cancer
-
2:16
sip-t treatment for metastatic castration-resistant prostate cancer
-
1:51
management of biochemical recurrence in prostate cancer